Gene therapy using CaMKII inhibitors has recently been applied successfully in a mouse model of catecholaminergic polymorphic ventricular tachycardia (Bezzerides et al., 2019). Here, CAMK2G is linked to catecholaminergic polymorphic ventricular tachycardia.